Compare ABLV & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | ABLV | XLO |
|---|---|---|
| Price | $0.74 | $0.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 19.6K | ★ 427.5K |
| Earning Date | 09-30-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $15.66 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $0.59 | $0.57 |
| 52 Week High | $1.77 | $1.70 |
| Indicator | ABLV | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 38.75 |
| Support Level | $0.65 | $0.57 |
| Resistance Level | $0.77 | $0.65 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 64.29 | 24.33 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.